Expression of the transcription repressor Gfi-1 is required for the maintenance of murine hematopoietic stem cells. In human cells, ectopic expression of Gfi-1 inhibits and RNA interference-mediated Gfi-1 downregulation enhances proliferation and colony formation of p210BCR/ABL expressing cells. To investigate the molecular mechanisms that may explain the effects of perturbing Gfi-1 expression in human cells, Gfi-1-regulated genes were identified by microarray analysis in K562 cells expressing the tamoxifen-regulated Gfi-1-ER protein.
INTRODUCTION
The process of hematopoiesis is regulated by a network of transcription factors acting cooperatively or antagonistically on multipotent or lineage-restricted hematopoietic progenitors. 1 Genetic evidence indicates that 'graded' expression of some transcription factors (i.e., PU.1, c-Myb and C/EBPa) has profound consequences for the expansion of certain hematopoietic cell compartments or for lineage choice. 2 --5 The critical importance of transcription factor expression levels for the coordinated regulation of early (i.e., self-renewal or commitment) and late (multipotent versus lineage-restricted differentiation) stages of normal hematopoiesis is also emphasized by a large body of evidence pointing out to deregulated transcription factor expression/ activity as a mechanism, which promotes leukemic transformation. 6 Conversely, perturbation of transcription factor levels can suppress the proliferation and survival of leukemic cells, 6 suggesting that their biological effects can be exploited for therapeutic purposes in leukemic cells.
C/EBPa exemplifies a transcription factor with distinct roles in normal and leukemic cells because it regulates the balance between differentiation and proliferation in the early stages of normal myelopoiesis 5, 7 but is functionally or genetically inactivated in many types of myeloid leukemia in which the homeostatic coordination between proliferation and differentiation is lost. 8, 9 Moreover, when ectopically expressed it induces differentiation and inhibits proliferation of myeloid leukemia lines and primary cells from patients with chronic myelogenous leukemia (CML)-blast crisis. 10 --13 These effects are important for optimal suppression of p210BCR/ABL-dependent leukemia in mice as expression of a DNA binding-deficient mutant which does not induce granulocytic differentiation 13, 14 did not prolong survival of leukemic mice as effectively as expression of transcriptionactivation competent C/EBPa. 14 Although granulocytic differentiation of p210BCR/ABL-expressing cells is only induced by DNA binding and transcription activation-competent C/EBPa proteins, 14 the role of transcription activation for the anti-proliferative effects of C/EBPa is less clear. We have shown that a DNA binding-deficient C/EBPa mutant suppresses the proliferation of p210BCR/ABL-transformed cells 14 and others have demonstrated that the interaction of C/EBPa with cell cycle regulatory and chromatin remodeling proteins is sufficient for proliferation inhibition. 15 --18 Nevertheless, we searched for transcriptionally regulated biologically relevant targets of C/EBPa that may explain its antiproliferative effects by oligonucleotide microarray hybridization with RNA of p210BCR/ABL-transformed cells expressing wild type or DNA binding-deficient C/EBPa. 19 One of the genes whose expression was activated by C/EBPa in a DNA binding-dependent manner is the transcriptional repressor Gfi-1, 19 which has a dual function in hematopoietic cells: maintenance of stem cells and differentiation of late granulocytic progenitors. 20 --24 We showed that Gfi-1 is a direct C/EBPa target and that its expression is required for C/EBPa-dependent inhibition of proliferation but not for induction of differentiation in K562 cells. 19 Moreover, expression of wild-type Gfi-1 but not of the transcription repression defective Gfi-1 P2A mutant inhibited proliferation and colony formation of p210BCR/ABL-expressing cell lines and primary CML cells, 19 suggesting that Gfi-1-regulated genes may be targeted for therapeutic purposes in p210BCR/ABLtransformed cells. We show here that the effects of Gfi-1 depend, in part, on transcriptional repression of the expression of STAT 5B and Mcl-1, two genes required for proliferation and survival of hematopoietic stem cells. 25 --28 Moreover, genetic or pharmacological inhibition of STAT 5 and Mcl-1 expression/activity markedly suppresses proliferation and colony formation of p210BCR/ABLexpressing cells including primary CD34 þ CML cells.
MATERIALS AND METHODS Reagents
Obatoclax (Gemin X Pharmaceuticals, Malvern, PA, USA), Pimozide (SigmaAldrich, St Louis, MO, USA) and Stat5 inhibitor (Novagen, San Diego, CA, USA) were dissolved in DMSO (10, 39 and 25 mM, respectively) and stored at 4 or À 20 1C.
Plasmids
MigRI-Gfi-1 and MigRI-Gfi-1 P2A were the kind gift of Dr J Zhu (Laboratory of Immunology, NIH).
MigRI-Gfi-1-ER was generated by polymerase chain reaction (PCR) as described. 19 pMSCV/IRES/YFP STAT5a H299R, S771F was cloned by releasing STAT5aH299R, S711F from pDNR STAT5 1*6 (ref. 29) and cloning it at EcoRI/XhoI restriction digestion sites of pMSCV/IRES/YFP.
The FG12 Mcl-1/IRES-GFP lentivirus was kindly provided by Dr Maria S Soengas (Spanish National Cancer Centre, Madrid, Spain).
The Mcl-1 shRNA/GFP lentivirus 30 was kindly provided by Dr M Andreeff (MD Anderson Hospital, Houston, TX, USA).
The STAT-5 and Mcl-1 shRNA pLKO.1 lentiviruses were purchased from Open Biosystems (Huntsville, AL, USA).
The promoter of the human STAT 5B gene (nucleotides À3464 to À3227) was obtained by PCR using the forward 5 0 -TGTGCCTAGAGCTG CAAGAA-3 0 and the reverse 5 0 -AAAATTAGCTGGGCATGGTG-3 0 and cloned at the SacI/XhoI sites of the pGL3 basic vector. The Gfi-1-binding site (b.s.) MUT STAT 5B promoter/Luc plasmid was generated by mutagenesis from wild-type STAT-5B/Luc plasmid.
The proximal promoter of the human Mcl-1 gene (nucleotides À661 to þ 255) was amplified by PCR using the forward 5 0 -CCTATATGTAAATAG CACCAAG-3 0 and the reverse 5 0 -GGCCTCCTTCTCCGTAGCC-3 0 and cloned at the EcoRV site of the pGL3 basic vector. The Gfi-1-b.s. MUT Mcl-1 promoter/ Luc plasmid was generated by mutagenesis from the À661 þ 255 wildtype Mcl-1/Luc plasmid.
The deletion mutant À201 to þ 255 Mcl-1/Luc plasmid was generated by cloning a PCR fragment obtained with the forward 5 0 -TTACGTAACCGG CACTCAGA-3 0 and the reverse-5 0 -GCCTCCTTCTCCGTAGCC-3 0 at the SacI/ XhoI sites of the basic pGL3 vector. The K562-C/EBPa-ER and the K562-C/EBPa-ER/Gfi-1shRNA cell lines were previously described. 19 Cell proliferation and colony formation assays Proliferation (counts of viable cells), cell cycle analysis and colony formation assays of parental and derivative K562 cells were performed as described. 19 
Cell cultures and viral infection

Real-time Q-PCR analysis
For real-time Q-PCR, total RNA was isolated using the RNeasy Mini kit (Qiagen, Hilden, Germany), digested with DNase --RNase free (Roche, Nutley, NJ, USA) for 1 h at 37 o C and deactivated for 15 min at 65 1C. In all, 2 mg was reverse-transcribed and the resulting cDNA was used as PCR template. All reactions were done in triplicate. Primer pairs designed using the ABI primer expression software are: human STAT 5B FW
. Real-time PCR was done using the GoTaq qPCR Master Mix (Promega) in a MyiQ thermocycler (Bio-Rad, Hercules, CA, USA) and quantified using MyiQ software (Bio-Rad). HPRT, a housekeeping gene with constant expression, was used as an internal control to normalize input cDNA. For relative comparison of each gene, we used the MyiQ software that analyzed the Ct value of real-time PCR signals with the DDCt method.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed using the EZ-ChIP assay kit (Upstate Biotechnology, Lake Placid, NY, USA). Briefly, exponentially growing Gfi-1-ER-K562 cells (untreated or 4-hydroxytamoxifen (4-HT)-treated, 24 h) were cross-linked with 1% formaldehyde, incubated for 10 min at room temperature and treated with glycine (125 mM for 5 min at room temperature). Cells were then washed with ice-cold phosphate-buffered serum, resuspended in lysis buffer (1 ml) in the presence of protease inhibitors and sonicated at 28% power for 12 pulses of 10 s each in a Branson Sonifer 450 (Branson Ultrasonics, Danbury, CT, USA). Chromatin was pre-cleared with 50 ml of protein A-agarose beads for 60 min at 4 1C with rotation, and pre-cleared lysates were immunoprecipitated with the Gfi-1 inhibits proliferation and colony formation R Soliera et al antiestrogen receptor a antibody (12 mg; SRA-1010, Enzo Life Sciences, Farmingdale, NY, USA) at 4 1C overnight. Immunoprecipitations without antibody (no antibody control) and an anti-mouse IgG were included in each experiment. Immune complexes were collected with 50 ml of protein A-agarose beads for 60 min at 4 1C (except for 10 ml of supernatant of the no antibody control, saved as input) and washed once with 1 ml each of: low-salt buffer (0.1% SDS; 1% Triton X-100; 2 mM EDTA; 20 mM Tris-HCl, pH 8.0 and 150 mM NaCl), high-salt buffer (0.1% SDS; 1% Triton X-100; 2 mM EDTA; 20 mM Tris-HCl, pH 8.0 and 1.5 M NaCl), LiCl buffer (250 mM LiCl; 1% NP-40; 1% sodium deoxycholate; 1 mM EDTA and 10 mM Tris-HCl, pH 8.0); and twice with 10 mM Tris-HCl, pH 8.0 and 1 mM EDTA. Then, complexes were eluted with elution buffer (1% SDS and 0.1 M NaHCO 3 ). Cross-links were reversed by heating at 65 1C overnight in the presence of 0.2 M NaCl. ChIP DNA (2 ml) was next used as a template for real time Q-PCR using the STAT 5B (sense 5 Luciferase reporter assays 293T cells plated into six-well plates at 35 Â 10 4 cells per well and cultured overnight were transfected the following day with 1.5 mg of wild-type or mutant STAT 5B or Mcl-1 promoter-Luc plasmids, 1/50 of Renilla reporter, and the MigRI empty vector or MigRI-Gfi-1 or MigRI-Gfi-1P2A expression vector for a total of 6 mg DNA per well using the Profection Mammalian Transfection System (Promega). After 48 h, cells were washed, lysed and levels of firefly and Renilla luciferase activities measured using a dual luciferase assay kit (Promega). All transfections were performed in triplicates in three independent experiments.
Microarray analysis
RNA was isolated from 4-HT-or vehicle-treated Gfi-1-ER K562 cells, purified with RNAesy Column (Qiagen) and used to generate biotin labeled cRNA.
In all, 10 mg of cRNA were fragmented and hybridized to HGU133 2.0 Plus arrays (Affymetrix, Santa Clara, CA, USA). Signal values were determined using Gene Chip Operating System 1.0 (GCOS, Affymetrix). A qualifier was considered to be differentially expressed if: (i) was detected in at least 50% of the samples, (ii) the fold change was at least 1.5 and (iii) the P-value based on t-test was p0.05.
Statistical analyses
Means were compared using the unpaired, two-tailed Student's t-test. A P-value of o0.05 was considered statistically significant in all calculations.
RESULTS
Wild-type Gfi-1 represses STAT 5B and Mcl-1 expression in K562 cells To identify transcription-regulated Gfi-1 targets, which may be responsible for its biological effects, Gfi-1-regulated genes were identified by probing oligonucleotide microarrays with RNA from 4-HT-treated (12 or 24 h) Gfi-1-ER-K562 or MigRI-K562 cells.
In triplicate experiments, expression of B850 genes was downregulated or upregulated X1.5-fold upon Gfi-1 activation. Among the downregulated genes, expression of STAT 5B and Mcl-1 mRNA was reduced 1.6-and 1.5-fold, respectively (P40.001 for both); of interest, expression of STAT 5A was also decreased (1.2-fold;
The decrease in STAT 5B and Mcl-1 transcripts in 4-HT-treated Gfi-1-ER-K562 cells was confirmed by real-time PCR (Figures 1a and b) . Of interest, expression of STAT 5A was also decreased (Supplementary The functional relationship between Gfi-1 and STAT 5 or Mcl-1 expression was also assessed in primary CD34 þ CML cells; CD34 þ cells from two CM-chronic phase samples were transduced with a Puro-Gfi-1 shRNA lentivirus able to downregulate Gfi-1 expression; 19 after selection in the presence of puromycin to kill residual non-transduced cells, lysates were prepared and subjected to western blotting to assess Gfi-1, Mcl-1 and STAT 5 expression. Gfi-1-silenced CML CD34 þ cells express higher levels of STAT 5 and Mcl-1 than the scramble-transduced counterpart (Figure 1d ).
STAT 5B and Mcl-1 are direct Gfi-1 targets Search of the human STAT 5B promoter using transcription factor b.s. databases (i.e., www.gene-regulation.com) identified a putative Gfi-1-b.s. at nucleotides À3350 to À3344. Thus, we cloned the À3464 to À3227 promoter region in the basic pGL3-Luc plasmid and performed luciferase assays in 293T cells co-transfected with wild-type Gfi-1 or the transcription repression-deficient Gfi-1P2A mutant. In three independent experiments, STAT 5B-driven luciferase activity was repressed approximately two-fold by wild-type Gfi-1 (Figure 2a) Gfi-1 inhibits proliferation and colony formation R Soliera et al we performed luciferase assays using a reporter plasmid in which the putative Gfi-1-b.s. (5 0 -AAATC-3 0 ) at nucleotides À3349 to À3345 was mutated into the sequence 5 0 -AGTTA-3 0 . As shown in Figure 2b , expression of wild-type Gfi-1 had minimal effects on the activity of this mutated promoter. PCR amplification of anti-ER chromatin immunoprecipitates from lysates of 4-HT-treated Gfi-1-ER/K562 cells revealed that Gfi-1 bound segments of the STAT 5B promoter near to or including the putative Gfi-1-b.s. responsible for Gfi-1-dependent repression of STAT 5B promoter activity but not a more proximal promoter segment, which does not include putative Gfi-1-b.s.s (Figures 2c and d) .
Luciferase assays were also performed on cell extracts of 293T cells co-transfected with the Mcl-1 5 0 flanking sequence (À661 to þ 255)-Luc plasmid and the wild type or Gfi-1P2A expression vector. Luciferase activity driven by this segment of the Mcl-1 promoter was repressed upon expression of wild type Gfi-1 but not of the transcription repressiondeficient Gfi-1P2A mutant (Figure 3a) . Search of this region of the Mcl-1 promoter identified a putative Gfi-1-b.s. at nucleotides À311 to À307 (5 0 -AAATC-3 0 ). Thus, we assessed the luciferase activity of a deletion mutant (À201 to þ 255 Mcl-1/Luc) lacking this putative b.s. after co-transfection of 293T cells with Gfi-1 or the Gfi-1P2A mutant. Expression of wild-type Gfi-1 induced only a modest (B20%) decrease in luciferase activity (Figure 3b) , suggesting that the À661 to À202 segment of the Mcl-1 promoter contains a functional Gfi-1-b.s. Thus, we generated a reporter plasmid (À661 to þ 255 Mcl-1 (Gfi-1 b.s. MUT)/Luc with a non-functional putative Gfi-1-b.s. at nucleotides À311 to À307 and assessed Gfi-1-regulated luciferase activity in 293T cells. Wild-type Gfi-1 still repressed luciferase activity driven by the mutant promoter but less than that driven by the promoter with an intact Gfi-1-b.s. (Figure 3c , compare panels a and c); this suggests that additional Gfi-1-b.s.(s) downstream of that at nucleotides À311 to À307 may be involved in the Gfi-1-dependent repression of the Mcl-1 promoter or that Gfi-1 regulates the Mcl-1 promoter, in part, via indirect mechanisms. As expression of STAT 5 is repressed by Gfi-1 (this study) and the Gfi-1-regulated (661 to þ 255) Mcl-1 promoter contains a putative STAT 5-b.s. at nucleotides À231 to À226, we reasoned that the effects of Gfi-1 on the Mcl-1 promoter may depend, in part, on repression of STAT 5B expression. However, ectopic expression of STAT 5B did not enhance luciferase activity driven by the À661 to þ 255 Mcl-1 promoter (data not shown), suggesting that Gfi-1 is unlikely to repress the Mcl-1 promoter via STAT 5. Moreover, wild-type Gfi-1 was still able to repress the activity of the À201 to þ 255 Mcl-1 promoter, which lacks the putative STAT 5-b.s. (Figure 3b To assess whether the effect of Gfi-1 can be rescued by expression of STAT 5B and/or Mcl-1, we generated derivative Gfi-1-ER-K562 cell lines expressing STAT 5B, Mcl-1 or both and assessed colony formation upon treatment with 4-HT. As shown in Figures 4a and b , expression of STAT 5B or Mcl-1 rescued, in part, the colony formation inhibitory effect of Gfi-1; however, expression of both blocked completely the effect of Gfi-1 (Figure 4c) . Thus, the effects of Gfi-1 could be mimicked by inhibition of STAT 5 and Mcl-1 expression and/or activity. Obatoclax is a pan-Bcl-2 inhibitor which also blocks the activity of Mcl-1.
32,33
Thus, we treated K562 cells with Obatoclax (500 nM) and assessed their proliferation and colony formation.
Compared with untreated cells, the number of Obatoclaxtreated K562 cells was markedly reduced at each time point (Figure 7a ). Obatoclax-treated cells showed a decrease in the S and G2/M phases and B35% of the cells exhibited hypodiploid DNA content indicative of apoptosis (Figure 7b) .
The decrease in proliferation and survival of Obatoclax-treated cells was confirmed by methylcellulose clonogenic assays. As shown in Figure 7c , clonogenic cells were o5% after treatment with Obatoclax. An identical inhibitory effect on colony formation was also observed upon Obatoclax treatment of the tyrosine kinase inhibitor-resistant T315I-K562 derivative line (Figure 7d) .
Colony assays were also performed using Obatoclax-treated CD34 þ cells from normal donors or CML chronic phase patients; as shown in Figure 8a , treatment with Obatoclax markedly decreased the number of clonogenic CD34 þ CML cells whereas a larger fraction of normal cord blood CD34 þ cells was spared especially upon treatment with a concentration of 100 nM. The effect of Obatoclax was also assessed on the CD34 þ CD38 þ and the CD34 þ CD38À subsets purified from three CML samples; as shown in Figure 8b , treatment with Obatoclax appears to suppress with the same efficiency colony formation derived from these two progenitor subsets. To further investigate the effect of Obatoclax on these progenitor subsets, secondary colony formation assays were performed from two CML samples using cells from solubilized methylcellulose plates ( Figure 8c) ; treatment with Obatoclax led to an almost complete suppression of colony formation from both subsets. Of interest, cells derived from the Obatoclax-treated CD34 þ CD38À subset and re-plated in methylcellulose without any treatment (no treatment colonies) formed fewer colonies of the CD34 þ CD38 þ counterpart (Figure 8c) , suggesting that the more primitive CML progenitors may be exquisitely sensitive to Obatoclax treatment.
We also assessed the effects of N'-((4-oxo-4H-chromen-3-yl) methylene) nicotinohydrazide (Novagen) and pimozide, 34 two recently described STAT 5 inhibitors; however, neither suppressed proliferation and colony formation of K562 cells as effectively as Obatoclax (Supplementary Figure 3) .
DISCUSSION
We reported previously that the transcription repressor Gfi-1 is a C/EBPa-regulated gene required for its proliferation-inhibitory effects but not for induction of myeloid differentiation in p210BCR/ABL-transformed cells. 19 Moreover, silencing of Gfi-1 expression in primary CD34 þ CML cells led to markedly increased primary and secondary colony formation, 19 although these cells were no longer able to form colonies after the fourth or fifth re-plating (data not shown). Based on these observations and the finding that ectopic expression of Gfi-1 suppressed colony formation of CD34 þ CML cells, 19 we reasoned that Gfi-1 may repress the expression of genes important for the proliferation and/or survival of primitive hematopoietic progenitors and that the products of these genes may be targeted by genetic or pharmacological approaches in leukemic cells. Candidate Gfi-1-regulated genes were identified in K562 cells expressing the 4-HTregulated Gfi-1-ER protein. After 12 h of 4-HT treatment, almost 850 genes were downregulated or upregulated X1.5-fold; the upregulated genes were B200, suggesting that some of the changes in gene expression induced by Gfi-1 may be indirect and/ or Gfi-1 has hitherto overlooked transcription-enhancing effects. Among the genes whose expression was downregulated upon Gfi-1 activation, STAT 5B and Mcl-1 attracted our attention because of their involvement in proliferation and survival of hematopoietic stem cells. 25 --28 Both genes appear to be transcriptionally repressed by Gfi-1 directly. The Mcl-1 5 0 flanking region used in our luciferase assays contains a STAT 5 putative b.s. and previous studies suggested that the expression of Mcl-1 may be regulated by STAT 5 transcriptionally; 35, 36 however, overexpression of STAT 5B did not enhance luciferase activity driven by the Mcl-1 promoter in 293T cells. Moreover, silencing of STAT 5 expression in K562 cells only induced a modest decrease in Mcl-1 expression (data not shown), suggesting that STAT 5 downregulation is not crucial for the effects of Gfi-1 on Mcl-1 expression.
In a recent study investigating the role of Gfi-1 in normal hematopoiesis, 37 Gfi-1 knockout mice showed an expansion of early myeloid progenitors associated with increased expression of HoxA9, Pbx1 and Meis1, which appear to be direct targets of Gfi-1. However, expression of HoxA9 is low in K562 cells and activation of Gfi-1 did not induce a decrease in HoxA9 levels, suggesting that Gfi-1 exerts its effects through multiple downstream effectors.
The functional relationship between Gfi-1 and STAT 5B and Mcl-1 is supported by the increased expression of STAT 5 and Mcl-1 in Gfi-1-silenced primary CD34 þ CML cells and by the finding that the colony formation inhibitory effect of Gfi-1 on K562 cells was rescued by expression of STAT 5B and/or Mcl-1.
Together, these studies suggest that Gfi-1 has an intermediate role in a C/EBPa-dependent regulatory pathway whereby increased levels of C/EBPa promote a decrease in the expression of proliferation and survival regulatory genes such as STAT 5B and Mcl-1. Indeed, activation of C/EBa in K562 cells induced a decrease in the expression of STAT 5 and Mcl-1, which was blocked in Gfi-1-silenced C/EBPa-ER-K562 cells (Supplementary Figure 4) . The decrease in expression/activity of STAT 5 and Mcl-1 may be important not only for the ability of different levels of C/EBPa expression to influence self-renewal and commitment to granulocyte/monocyte progenitors of normal hematopoietic stem/ progenitor cells, 5, 7 but also for the consequences on the proliferation and survival of myeloid leukemia cells.
Although downregulation of STAT 5 and Mcl-1 expression has been implicated in the antileukemia effects of several compounds such as sorafenib, PKC-412, omacetaxine and quercetin, 38 --41 there is no direct genetic evidence in support of an essential role of these two genes for the proliferation and survival of p210BCR/ ABL-transformed cells. As shown here, STAT 5 or Mcl-1 downregulation led to a complete eradication of K562 clonogenic cells and markedly suppressed colony formation of CD34 þ CML cells. Compared with K562 cells, the less potent inhibitory effect on colony formation of CML primary cells probably reflects the residual expression of these two proteins in primary CML cells rather than an intrinsic differential requirement for STAT 5 and/or Mcl-1 between K562 and primary CD34 þ CML cells.
Although specific pharmacological inhibitors of Mcl-1 and STAT 5B
are not yet available, we thought that it would be informative to test whether Obatoclax, a Bcl-2 family antagonist, which also inhibits Mcl-1, 32 and Pimozide, a neuroleptic drug recently identified as an inhibitor of STAT 5-dependent transcription, 34 would be as effective as STAT 5 and Mcl-1 RNA interference in suppressing proliferation and survival of p210BCR/ABL-transformed cells.
Although preliminary, our data suggest that Obatoclax is highly effective in inhibiting colony formation of CD34 þ CML cells (including the more primitive CD34 þ CD38À subset) and could be used at concentrations that may spare a high proportion of normal progenitors; in comparison, Pimozide is considerably less effective even if used at micromolar concentrations.
In summary, Gfi-1 appears to be a crucial mediator of the proliferation and survival inhibitory effects of C/EBPa in p210BCR/ ABL-transformed cells via transcription repression of STAT 5B and Mcl-1, two 'usual suspects' for an important role in normal hematopoiesis and in leukemogenesis. 25 --28 The functional relationship between Gfi-1 and STAT 5B, and Mcl-1 expression is likely to be altered in other types of myeloid leukemia with genetic or functional inactivation of C/EBPa; 8,9 like p210BCR/ABL-transformed cells, these leukemic cells may also rely on STAT 5 and Mcl-1 expression and be exquisitely sensitive to inhibition of their activity.
